Natera, Inc.'s Chief Legal Officer Sells $4.6 Million in Stock, Reports Strong Q4 Results and Collaborates on Colorectal Cancer Trial
Natera, Inc.'s SEC and Chief Legal Officer, Daniel Rabinowitz, recently sold 19,672 shares of common stock for approximately $4.6 million. The sales took place on January 20 and 21, 2026, at prices ranging from $234.7384 to $235 per share. Rabinowitz sold 19,234 shares on January 20 at $234.7384 per share and an additional 438 shares on January 21 at $235 per share. He also acquired 856 shares through the exercise of restricted stock units on January 20 at no cost.
Natera, Inc. reported strong preliminary fourth-quarter 2025 results, with revenue expected to increase by nearly 40% year-over-year, exceeding analyst forecasts. The company also saw a 17% rise in test volume during the same period. In partnership news, Natera and Exelixis announced a collaboration on a phase 3 trial for colorectal cancer patients, utilizing Natera's Signatera test to identify patients with molecular residual disease for trial participation. Canaccord Genuity reiterated its Buy rating for Natera with a price target of $285.00 following these positive preliminary results.
Natera introduced a new multi-modal artificial intelligence model designed to enhance molecular residual disease assessment in cancer patients by integrating various data types, including circulating tumor DNA and digital pathology imaging. The company is also set to present data from its EXPAND clinical trial on fetal genetic screening at an upcoming Society for Maternal-Fetal Medicine meeting, aiming to validate a screening test for detecting inherited disease-causing variants in fetuses. Additionally, a study published in JAMA Oncology highlighted improved survival in colorectal cancer patients treated with celecoxib, with Natera's Signatera test aiding in detecting minimal residual disease.
AI technology is revolutionizing the stock market, with Investing.com's ProPicks AI offering winning stock portfolios selected by advanced AI algorithms. Year to date, 2 out of 3 global portfolios have outperformed their benchmark indexes, with 88% showing positive returns. The Tech Titans strategy, a flagship portfolio, has doubled the S&P 500 in 18 months, featuring successful investments in companies like Super Micro Computer (+185%) and AppLovin (+157%). Stay tuned to discover the next potential stock poised for significant growth.